Your Money at Work

JDRF has a bold plan for the future of type 1 diabetes (T1D) research in Canada. As better treatments unfold and the prospect of curing this disease rests on the horizon, we remain ever-committed to directing more resources to launch and sustain innovative research and clinical trials from coast-to-coast. Transforming Lives: Today and Tomorrow is our solution to accelerating diabetes breakthroughs in partnership with the community we support.


Facts on JDRF Canada’s investment in T1D research

In 2017, JDRF Canada has increased dollars directed to research by 6.5% and secured a new partnership with the Canadian Institutes of Health Research for a total $30M investment of new dollars to support type 1 diabetes research.

  • In 2017, JDRF Canada has increased dollars to research by 6.5%. This has been achieved through support from the community and growing fundraising revenue.  
  • In 2017, JDRF announced a new partnership with The Government of Canada, through the Canadian Institutes of Health Research (CIHR), to support innovative clinical trials research for type 1 diabetes. Both CIHR and JDRF have committed $15M to the partnership, for a total investment of $30M.
  • This represents a net new investment of dollars to type 1 diabetes research.

JDRF Canada works closely with the type 1 diabetes community to ensure their voices are heard

  • In 2017, JDRF Canada advocated on behalf of the type 1 diabetes community and worked closely with Diabetes Canada to ensure the community’s concerns regarding the denial of Disability Tax Credit (DTC) claims were heard.
  • Thousands of Canadians came forward and rallied with JDRF – sharing their stories, taking action and advocating on this issue. Working together, our voices were louder and our message was heard by decision makers.
  • In December 2017, JDRF and the type 1 community welcomed the Government of Canada and the CRA announcement that they will rescind new letters introduced in May that made it virtually impossible for adults with type 1 diabetes to qualify for the disability tax credit (DTC). The CRA also committed to review all applications previously denied under the post-May 2017 process. This represented a big win for the T1D community and JDRF.

JDRF is the largest global private funder of research to cure, prevent and treat type 1 diabetes

  • As the largest global private funder of research to cure, prevent and treat type 1 diabetes (T1D), no organization is more passionate, more committed and more impatient to put an end to T1D than JDRF.
  • JDRF funds research in 18 countries, directing funds to support the best research projects and investigators around the globe.
Facts on JDRF’s International investment in T1D research
  • In 2017, JDRF allocated $100 million toward research globally. This does not include funds that were allocated into the JDRF T1D Fund – which alone manages $60 million and itself invested more than $10 million in high-impact research focused on developing life-changing therapies for type 1 diabetes (T1D). 
  • JDRF is using its position to generate substantial funding from other sources.
    • Last year alone, an extra $214 million went to T1D research because our corporate, foundation, and government partnerships generate funding beyond what we raise at JDRF. That’s more than our annual budget and it happens because of a concerted effort across our organization.
    • Through relentless advocacy, JDRF has generated $2.5 billion in research funding for the Special Diabetes Program at the National Institutes of Health.
  • Today, there are more than 500 active grants and 70 clinical trials that we have funded directly.
  • In 2017, JDRF advanced 25 potential therapies to significant, new stages of development. 


JDRF's research mission is to discover, develop, and deliver advances that cure, better treat, and prevent T1D. As the global leader in the fight against T1D, JDRF's research programs are comprehensive – addressing the hopes and dreams of every person with T1D for the best quality of life and a cure for this disease.

Lets turn type one into type none